Management of neovascular age-related macular degeneration: current state-of-the-art care for optimizing visual outcomes and therapies in development

References

• KleinRKleinBELintonKLPrevalence of age-related maculopathy. The Beaver Dam Eye StudyOphthalmology19929969339431630784
   PubMed Web of Science ®Google Scholar
• CongdonNO’ColmainBKlaverCCEye Diseases Prevalence Research GroupCauses and prevalence of visual impairment among adults in the United StatesArch Ophthalmol2004122447748515078664
   PubMed Web of Science ®Google Scholar
• FriedmanDSO’ColmainBJMuñozBEye Diseases Prevalence Research GroupPrevalence of age-related macular degeneration in the United StatesArch Ophthalmol2004122456457215078675
   PubMed Web of Science ®Google Scholar
• WongWLSuXLiXGlobal prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysisLancet Glob Health201422e106e11625104651
   PubMed Web of Science ®Google Scholar
• SteinJDNewman-CaseyPAMrinaliniTLeePPHuttonDWCost-effectiveness of bevacizumab and ranibizumab for newly diagnosed neovascular macular degenerationOphthalmology2014121493694524405740
   PubMed Web of Science ®Google Scholar
• FerrisFL3rdFineSLHymanLAge-related macular degeneration and blindness due to neovascular maculopathyArch Ophthalmol198410211164016426208888
   PubMed Web of Science ®Google Scholar
• RasmussenASanderBLong-term longitudinal study of patients treated with ranibizumab for neovascular age-related macular degenerationCurr Opin Ophthalmol201425315816324663065
   PubMed Web of Science ®Google Scholar
• NguyenQDIntroduction: Neovascular age-related macular degeneration: approaches for improving visual acuity and reducing the burden of careOphthalmology20131205 SupplS1S223642780
   PubMed Web of Science ®Google Scholar
• TolentinoMJDennrickAJohnETolentinoMSDrugs in Phase II clinical trials for the treatment of age-related macular degenerationExpert Opin Investig Drugs20142242117
   Google Scholar
• SolomonSDLindsleyKVedulaSSKrzystolikMGHawkinsBSAnti-vascular endothelial growth factor for neovascular age-related macular degenerationCochrane Database Syst Rev20148CD00513925170575
   PubMed Web of Science ®Google Scholar
• HanoutMFerrazDAnsariMTherapies for neovascular age-related macular degeneration: current approaches and pharmacologic agents in developmentBiomed Res Int2013201383083724319688
   PubMed Web of Science ®Google Scholar
• Schmidt-ErfurthUChongVLoewensteinAEuropean Society of Retina SpecialistsGuidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA)Br J Ophthalmol20149891144116725136079
   PubMed Web of Science ®Google Scholar
• KrauseLYousifTPohlKCAPTAIN study groupAn epidemiological study of neovascular age-related macular degeneration in GermanyCurr Med Res Opin201329101391139723944372
   PubMed Web of Science ®Google Scholar
• GangnonRELeeKEKleinBEIyengarSKSivakumaranTAKleinRSeverity of age-related macular degeneration in 1 eye and the incidence and progression of age-related macular degeneration in the fellow eye: the Beaver Dam Eye StudyJAMA Ophthalmol2015133212513225340497
   PubMed Web of Science ®Google Scholar
• WongTYChakravarthyUKleinRThe natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysisOphthalmology2008115111612617675159
   PubMed Web of Science ®Google Scholar
• LoewensteinAThe significance of early detection of age-related macular degeneration: Richard & Hinda Rosenthal Foundation lecture, The Macula Society 29th annual meetingRetina200727787387817891011
   PubMed Web of Science ®Google Scholar
• BakriSJMoshfeghiDMFrancomSIntraocular pressure in eyes receiving monthly ranibizumab in 2 pivotal age-related macular degeneration clinical trialsOphthalmology201412151102110824393349
   PubMed Web of Science ®Google Scholar
• American Academy of OphthalmologyAge-Related Macular DegenerationPreferred Practice Pattern® GuidelineSan Francisco, CAAmerican Academy of Ophthalmology2014 Available at: http://www.aao.org/Assets/db935a77-1997-4d60-b850-71-b7602f46e2/635582143853270000/age-related-macular-degeneration-ppp-pdfAccessed May 21, 2015
   Google Scholar
• DoDVGowerEWCassardSDDetection of new-onset choroidal neovascularization using optical coherence tomography: the AMD DOC StudyOphthalmology2012119477177822297028
   PubMed Web of Science ®Google Scholar
• DoDVDetection of new-onset choroidal neovascularizationCurr Opin Ophthalmol201324324424723518615
   PubMed Web of Science ®Google Scholar
• MalamosPSacuSGeorgopoulosMKissCPruenteCSchmidt-ErfurthUCorrelation of high-definition optical coherence tomography and fluorescein angiography imaging in neovascular macular degenerationInvest Ophthalmol Vis Sci200950104926493319494200
   PubMed Web of Science ®Google Scholar
• SaddaSRLiakopoulosSKeanePARelationship between angiographic and optical coherence tomographic (OCT) parameters for quantifying choroidal neovascular lesionsGraefes Arch Clin Exp Ophthalmol2010248217518419760223
   PubMed Web of Science ®Google Scholar
• KeanePAHeussenFMOuyangYAssessment of differential pharmacodynamic effects using optical coherence tomography in neovascular age-related macular degenerationInvest Ophthalmol Vis Sci20125331152116122281826
   PubMed Web of Science ®Google Scholar
• CastilloMMMowattGEldersAOptical coherence tomography for the monitoring of neovascular age-related macular degeneration: a systematic reviewOphthalmology2015122239940625444343
   PubMed Web of Science ®Google Scholar
• YannuzziLAIndocyanine green angiography: a perspective on use in the clinical settingAm J Ophthalmol20111515745751.e121501704
   PubMed Web of Science ®Google Scholar
• de BruinDMBurnesDLLoewensteinJIn vivo three-dimensional imaging of neovascular age-related macular degeneration using optical frequency domain imaging at 1050 nmInvest Ophthalmol Vis Sci200849104545455218390638
   PubMed Web of Science ®Google Scholar
• MiuraMMakitaSIwasakiTYasunoYThree-dimensional visualization of ocular vascular pathology by optical coherence angiography in vivoInvest Ophthalmol Vis Sci20115252689269521273541
   PubMed Web of Science ®Google Scholar
• HongYJMiuraMMakitaSNoninvasive investigation of deep vascular pathologies of exudative macular diseases by high-penetration optical coherence angiographyInvest Ophthalmol Vis Sci20135453621363123633664
   PubMed Web of Science ®Google Scholar
• JiaYBaileySTWilsonDJQuantitative optical coherence tomography angiography of choroidal neovascularization in age-related macular degenerationOphthalmology201412171435144424679442
   PubMed Web of Science ®Google Scholar
• ZhangYWangXRiveroEBPhotoreceptor perturbation around subretinal drusenoid deposits as revealed by adaptive optics scanning laser ophthalmoscopyAm J Ophthalmol20141583584596.e124907433
   PubMed Web of Science ®Google Scholar
• ZarbinMACasaroli-MaranoRPRosenfeldPJAge-related macular degeneration: clinical findings, histopathology and imaging techniquesDev Ophthalmol20145313224732758
   PubMedGoogle Scholar
• AREDS2-HOME Study Research GroupChewEYRandomized trial of a home monitoring system for early detection of choroidal neovascularization home monitoring of the Eye (HOME) studyOphthalmology2014121253554424211172
   PubMed Web of Science ®Google Scholar
• SimaderCRitterMBolzMMorphologic parameters relevant for visual outcome during anti-angiogenic therapy of neovascular age-related macular degenerationOphthalmology201412161237124524684838
   PubMed Web of Science ®Google Scholar
• ComynOSivaprasadSPetoTA randomized trial to assess functional and structural effects of ranibizumab versus laser in diabetic macular edema (the LUCIDATE study)Am J Ophthalmol2014157596097024531025
   PubMed Web of Science ®Google Scholar
• WuZAytonLNLuuCDGuymerRHRelationship between retinal microstructures on optical coherence tomography and microperimetry in age-related macular degenerationOphthalmology201412171445145224629618
   PubMed Web of Science ®Google Scholar
• van LandinghamSWMassofRWChanEFriedmanDSRamuluPYFear of falling in age-related macular degenerationBMC Ophthalmol2014141024472499
   PubMed Web of Science ®Google Scholar
• Age-Related Eye Disease Study Research GroupA randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8Arch Ophthalmol2001119101417143611594942
   PubMed Web of Science ®Google Scholar
• Age-Related Eye Disease Study 2 Research GroupLutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trialJAMA2013309192005201523644932
   PubMed Web of Science ®Google Scholar
• SanGiovanniJPChewEYAgrónEAge-Related Eye Disease Study Research GroupThe relationship of dietary omega-3 long-chain polyunsaturated fatty acid intake with incident age-related macular degeneration: AREDS report no. 23Arch Ophthalmol200812691274127918779490
   PubMedGoogle Scholar
• TanJSWangJJFloodVMitchellPDietary fatty acids and the 10-year incidence of age-related macular degeneration: the Blue Mountains Eye StudyArch Ophthalmol2009127565666519433717
   PubMedGoogle Scholar
• AronowMEChewEYAge-related Eye Disease Study 2: perspectives, recommendations, and unanswered questionsCurr Opin Ophthalmol201425318619024614146
   PubMed Web of Science ®Google Scholar
• AwhCCLaneAMHawkenSZankeBKimIKCFH and ARMS2 genetic polymorphisms predict response to antioxidants and zinc in patients with age-related macular degenerationOphthalmology2013120112317232323972322
   PubMed Web of Science ®Google Scholar
• ChewEYKleinMLClemonsTEAge-Related Eye Disease Study Research GroupNo clinically significant association between CFH and ARMS2 genotypes and response to nutritional supplements: AREDS report number 38Ophthalmology2014121112173218024974817
   PubMed Web of Science ®Google Scholar
• BresslerNMTreatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study GroupPhotodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2Arch Ophthalmol2001119219820711176980
   PubMed Web of Science ®Google Scholar
• Verteporfin In Photodynamic Therapy Study GroupVerteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization – verteporfin in photodynamic therapy report 2Am J Ophthalmol2001131554156011336929
   PubMed Web of Science ®Google Scholar
• OishiAMiyamotoNMandaiMLAPTOP study: a 24-month trial of verteporfin versus ranibizumab for polypoidal choroidal vasculopathyOphthalmology201412151151115224484991
   PubMed Web of Science ®Google Scholar
• KohALeeWKChenLJEVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathyRetina20123281453146422426346
   PubMed Web of Science ®Google Scholar
• TanCSNgoWKLimLWRe: Oishi et al.: LAPTOP study: a 24-month trial of verteporfin versus ranibizumab for polypoidal choroidal vasculopathy (Ophthalmology. 2014;121:1151–1152)Ophthalmology20151221e5e625542543
   PubMed Web of Science ®Google Scholar
• KohAExpert PCV PanelChenLJChenSJPolypoidal choroidal vasculopathy: evidence-based guidelines for clinical diagnosis and treatmentRetina201333468671623455233
   PubMed Web of Science ®Google Scholar
• IjiriSSugiyamaKShort-term efficacy of intravitreal aflibercept for patients with treatment-naïve polypoidal choroidal vasculopathyGraefes Arch Clin Exp Ophthalmol2015253335135725023147
   PubMed Web of Science ®Google Scholar
• HubschmanJPReddySSchwartzSDAge-related macular degeneration: current treatmentsClin Ophthalmol2009315516619668560
   PubMedGoogle Scholar
• BrownDMMichelsMKaiserPKHeierJSSyJPIanchulevTANCHOR Study GroupRanibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR studyOphthalmology200911615765.e519118696
   PubMed Web of Science ®Google Scholar
• RosenfeldPJBrownDMHeierJSMARINA Study GroupRanibizumab for neovascular age-related macular degenerationN Engl J Med2006355141419143117021318
   PubMed Web of Science ®Google Scholar
• RegilloCDBrownDMAbrahamPRandomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1Am J Ophthalmol2008145223924818222192
   PubMed Web of Science ®Google Scholar
• Schmidt-ErfurthUEldemBGuymerREXCITE Study GroupEfficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE studyOphthalmology2011118583183921146229
   PubMed Web of Science ®Google Scholar
• LalwaniGARosenfeldPJFungAEA variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO StudyAm J Ophthalmol200914814358.e119376495
   PubMed Web of Science ®Google Scholar
• BoyerDSHeierJSBrownDMFrancomSFIanchulevTRubioRGA Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degenerationOphthalmology200911691731173919643495
   PubMed Web of Science ®Google Scholar
• SingerMAAwhCCSaddaSHORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degenerationOphthalmology201211961175118322306121
   PubMed Web of Science ®Google Scholar
• HolzFGAmoakuWDonateJSUSTAIN Study GroupSafety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN studyOphthalmology2011118466367121459217
   PubMed Web of Science ®Google Scholar
• GrunwaldJEDanielEHuangJCATT Research GroupRisk of geographic atrophy in the comparison of age-related macular degeneration treatments trialsOphthalmology2014121115016124084496
   PubMed Web of Science ®Google Scholar
• GrunwaldJEPistilliMYingGSMaguireMGDanielEMartinDFComparison of Age-related Macular Degeneration Treatments Trials Research GroupGrowth of Geographic Atrophy in the Comparison of Age-related Macular Degeneration Treatments TrialsOphthalmology2015122480981625542520
   PubMed Web of Science ®Google Scholar
• CATT Research GroupMartinDFMaguireMGRanibizumab and bevacizumab for neovascular age-related macular degenerationN Engl J Med2011364201897190821526923
   PubMed Web of Science ®Google Scholar
• Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research GroupMartinDFMaguireMGRanibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year resultsOphthalmology201211971388139822555112
   PubMed Web of Science ®Google Scholar
• IVAN Study InvestigatorsChakravarthyUHardingSPRanibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trialOphthalmology201211971399141122578446
   PubMed Web of Science ®Google Scholar
• ChakravarthyUHardingSPRogersCAIVAN study investigatorsAlternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trialLancet201338299001258126723870813
   PubMed Web of Science ®Google Scholar
• KrebsISchmettererLBoltzAMANTA Research GroupA randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degenerationBr J Ophthalmol201397326627123292928
   PubMed Web of Science ®Google Scholar
• KodjikianLSouiedEHMimounGGEFAL Study GroupRanibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized TrialOphthalmology2013120112300230923916488
   PubMed Web of Science ®Google Scholar
• BergKPedersenTRSandvikLBragadóttirRComparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocolOphthalmology2015122114615225227499
   PubMed Web of Science ®Google Scholar
• HeierJSBrownDMChongVVIEW 1 and VIEW 2 Study GroupsIntravitreal aflibercept (VEGF trap-eye) in wet age-related macular degenerationOphthalmology2012119122537254823084240
   PubMed Web of Science ®Google Scholar
• WangQLiTWuZNovel VEGF decoy receptor fusion protein conbercept targeting multiple VEGF isoforms provide remarkable anti-angiogenesis effect in vivoPloS One201388e7054423950958
   PubMed Web of Science ®Google Scholar
• ZhangMZhangJYanMKH902 Phase 1 Study GroupA phase 1 study of KH902, a vascular endothelial growth factor receptor decoy, for exudative age-related macular degenerationOphthalmology2011118467267821146224
   PubMed Web of Science ®Google Scholar
• LiXXuGWangYAURORA Study GroupSafety and efficacy of conbercept in neovascular age-related macular degeneration: results from a 12-month randomized phase 2 study: AURORA studyOphthalmology201412191740174724793528
   PubMed Web of Science ®Google Scholar
• Chengdu Kanghong Biotech Co LtdA Randomized, Double-masked, Multicenter, Sham-controlled, Safety and Efficacy Study of KH902 in Patients With Wet AMD (PHOENIX)ClinicalTrials.gov [website on the Internet]Bethseda, MDUS National Library of Medicine2011 [updated March 21, 2014]. Available from: http://clinicaltrials.gov/ct2/show/NCT01436864.NLM. identifier: NCT01436864Accessed February 23, 2015
   Google Scholar
• RayessNHoustonSK3rdGuptaOPHoACRegilloCDTreatment outcomes after 3 years in neovascular age-related macular degeneration using a treat-and-extend regimenAm J Ophthalmol2015159138.e125217859
   PubMed Web of Science ®Google Scholar
• RofaghaSBhisitkulRBBoyerDSSaddaSRZhangKSEVEN-UP Study GroupSeven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP)Ophthalmology2013120112292229923642856
   PubMed Web of Science ®Google Scholar
• EldemBMMuftuogluGTopbaşSthe SALUTE study groupA randomized trial to compare the safety and efficacy of two ranibizumab dosing regimens in a Turkish cohort of patients with choroidal neovascularization secondary to AMDActa Ophthalmol2014 Epub August 27
   Web of Science ®Google Scholar
• SouiedEHDevinFMauget-FaÿsseMMP0112 Study GroupTreatment of exudative age-related macular degeneration with a designed ankyrin repeat protein that binds vascular endothelial growth factor: a phase I/II studyAm J Ophthalmol20141584724732.e224907435
   PubMed Web of Science ®Google Scholar
• O’BrienNJonesSTWilliamsDGProduction and characterization of monoclonal anti-sphingosine-1-phosphate antibodiesJ Lipid Res200950112245225719509417
   PubMed Web of Science ®Google Scholar
• SabbadiniRASphingosine-1-phosphate antibodies as potential agents in the treatment of cancer and age-related macular degenerationBr J Pharmacol201116261225123821091645
   PubMed Web of Science ®Google Scholar
• DongASeidelCSnellDAntagonism of PDGF-BB suppresses subretinal neovascularization and enhances the effects of blocking VEGF-AAngiogenesis201417355356224154861
   PubMed Web of Science ®Google Scholar
• LaiCMEstcourtMJWikstromMrAAV.sFlt-1 gene therapy achieves lasting reversal of retinal neovascularization in the absence of a strong immune response to the viral vectorInvest Ophthalmol Vis Sci20095094279428719357358
   PubMed Web of Science ®Google Scholar
• LaiCMEstcourtMJHimbeckRPPreclinical safety evaluation of subretinal AAV2.sFlt-1 in non-human primatesGene Ther20121910999100922071974
   PubMed Web of Science ®Google Scholar
• IgarashiTMiyakeKKatoKLentivirus-mediated expression of angiostatin efficiently inhibits neovascularization in a murine proliferative retinopathy modelGene Ther200310321922612571629
   PubMed Web of Science ®Google Scholar
• SchwartzSDRegilloCDLamBLHuman embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt’s macular dystrophy: follow-up of two open-label phase 1/2 studiesLancet2015385996750951625458728
   PubMed Web of Science ®Google Scholar
• SheridanCStem cell therapy clears first hurdle in AMDNat Biotechnol201432121173117425489818
   PubMed Web of Science ®Google Scholar
• KaiserPKBoyerDSCruessAFSlakterJSPilzSWeisbergerADENALI Study GroupVerteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelvemonth results of the DENALI studyOphthalmology201211951001101022444829
   PubMed Web of Science ®Google Scholar
• LarsenMSchmidt-ErfurthULanzettaPMONT BLANC Study GroupVerteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month MONT BLANC study resultsOphthalmology20121195992100022424834
   PubMed Web of Science ®Google Scholar
• HatzKSchneiderUHenrichPBBraunBSacuSPrünteCRanibizumab plus verteporfin photodynamic therapy in neovascular age-related macular degeneration: 12 months of retreatment and vision outcomes from a randomized studyOphthalmologica20152332667325471330
   PubMed Web of Science ®Google Scholar
• LaiTYLeeGKLukFOLamDSIntravitreal ranibizumab with or without photodynamic therapy for the treatment of symptomatic polypoidal choroidal vasculopathyRetina20113181581158821610566
   PubMed Web of Science ®Google Scholar
• EnglanderMKaiserPKCombination therapy for the treatment of neovascular age-related macular degenerationCurr Opin Ophthalmol201324323323823429601
   PubMed Web of Science ®Google Scholar
• ChanWMLaiTYWongALTongJPLiuDTLamDSCombined photodynamic therapy and intravitreal triamcinolone injection for the treatment of subfoveal choroidal neovascularisation in age related macular degeneration: a comparative studyBr J Ophthalmol200690333734116488958
   PubMed Web of Science ®Google Scholar
• ChaudharyVMaoAHooperPLSheidowTGTriamcinolone acetonide as adjunctive treatment to verteporfin in neovascular age-related macular degeneration: a prospective randomized trialOphthalmology2007114122183218918054638
   PubMed Web of Science ®Google Scholar
• AriasLGarcia-ArumiJRamonJMBadiaMRubioMPujolOPhotodynamic therapy with intravitreal triamcinolone in predominantly classic choroidal neovascularization: one-year results of a randomized studyOphthalmology2006113122243225016996600
   PubMed Web of Science ®Google Scholar
• KovacsKDQuirkMTKinoshitaTA retrospective analysis of triple combination therapy with intravitreal bevacizumab, posterior sub-tenon’s triamcinolone acetonide, and low-fluence verteporfin photodynamic therapy in patients with neovascular age-related macular degenerationRetina201131344645221336068
   PubMed Web of Science ®Google Scholar
• ForteRBonavolontàPBenayounYAdenisJPRobertPYIntravitreal ranibizumab and bevacizumab in combination with full-fluence verteporfin therapy and dexamethasone for exudative age-related macular degenerationOphthalmic Res201145312913420847575
   PubMed Web of Science ®Google Scholar
• EhmannDGarcíaRTriple therapy for neovascular age-related macular degeneration (verteporfin photodynamic therapy, intravitreal dexamethasone, and intravitreal bevacizumab)Can J Ophthalmol2010451364020130708
   PubMed Web of Science ®Google Scholar
• SchwartzSGScottIUFlynnHWJrStewartMWDrug delivery techniques for treating age-related macular degenerationExpert Opin Drug Deliv2014111616824219407
   PubMed Web of Science ®Google Scholar
• KauperKRiveraMMillsJDesign considerations and performance of a next-generation encapsulated cell technology intraocular implant delivering VEGF-antagonist [meeting abstract]Invest Ophthalmol Vis Sci20145513441
   Web of Science ®Google Scholar
• SaatiSLoRLiPYMengEVarmaRHumayunMSMini drug pump for ophthalmic useTrans Am Ophthalmol Soc2009107607020126483
   PubMedGoogle Scholar
• RauckBMFribergTRMedina MendezCABiocompatible reverse thermal gel sustains the release of intravitreal bevacizumab in vivoInvest Ophthalmol Vis Sci201455146947624370837
   PubMed Web of Science ®Google Scholar
• OlsenTWFengXWabnerKCsakyKPambuccianSCameronJDPharmacokinetics of pars plana intravitreal injections versus microcannula suprachoroidal injections of bevacizumab in a porcine modelInvest Ophthalmol Vis Sci20115274749475621447680
   PubMed Web of Science ®Google Scholar
• PescinaSFerrariGGovoniPIn-vitro permeation of bevcizumab through human sclera: effect of iontophoresis applicationJ Pharm Pharmacol20106291189119420796199
   PubMed Web of Science ®Google Scholar
• MurugappanSKZhouYTranssclera Drug Delivery by Pulsed High-Intensity Focused Ultrasound (HIFU): An Ex Vivo StudyCurr Eye Res2014117
   Web of Science ®Google Scholar
• SouiedEHLevezielNToward personalized medicine for age-related macular degenerationAm J Ophthalmol2012154342742822898343
   PubMed Web of Science ®Google Scholar
• HeierJSNeovascular age-related macular degeneration: individualizing therapy in the era of anti-angiogenic treatmentsOphthalmology20131205 SupplS23S2523642783
   PubMed Web of Science ®Google Scholar
• SundaresanPVashistPRavindranRDPolymorphisms in ARMS2/HTRA1 and complement genes and age-related macular degeneration in India: findings from the INDEYE studyInvest Ophthalmol Vis Sci201253127492749723060141
   PubMed Web of Science ®Google Scholar
• HainesJLHauserMASchmidtSComplement factor H variant increases the risk of age-related macular degenerationScience2005308572041942115761120
   PubMed Web of Science ®Google Scholar
• KleinRJZeissCChewEYComplement factor H polymorphism in age-related macular degenerationScience2005308572038538915761122
   PubMed Web of Science ®Google Scholar
• BairdPNHagemanGSGuymerRHNew era for personalized medicine: the diagnosis and management of age-related macular degenerationClin Experiment Ophthalmol200937881482119878229
   PubMed Web of Science ®Google Scholar
• YatesJRSeppTMatharuBKGenetic Factors in AMD Study GroupComplement C3 variant and the risk of age-related macular degenerationN Engl J Med2007357655356117634448
   PubMed Web of Science ®Google Scholar
• YanagisawaSKondoNMikiAA common complement C3 variant is associated with protection against wet age-related macular degeneration in a Japanese populationPloS One2011612e2884722174912
   PubMed Web of Science ®Google Scholar
• YangZCampNJSunHA variant of the HTRA1 gene increases susceptibility to age-related macular degenerationScience2006314580199299317053109
   PubMed Web of Science ®Google Scholar
• ChenWXuWTaoQMeta-analysis of the association of the HTRA1 polymorphisms with the risk of age-related macular degenerationExp Eye Res200989329230019026638
   PubMed Web of Science ®Google Scholar
• DeangelisMMJiFAdamsSAlleles in the HtrA serine peptidase 1 gene alter the risk of neovascular age-related macular degenerationOphthalmology2008115712091215.e718164066
   PubMed Web of Science ®Google Scholar
• KanoffJMillerJPharmacogenetics of the treatment response of age-related macular degeneration with ranibizumab and bevacizumabSemin Ophthalmol2013285–635536024010796
   PubMed Web of Science ®Google Scholar
• EdwardsAORitterR3rdAbelKJManningAPanhuysenCFarrerLAComplement factor H polymorphism and age-related macular degenerationScience2005308572042142415761121
   PubMed Web of Science ®Google Scholar
• HagstromSAYingGSPauerGJComparison of Age-Related Macular Degeneration Treatments Trials (CATT) Research GroupVEGFA and VEGFR2 gene polymorphisms and response to anti-vascular endothelial growth factor therapy: comparison of age-related macular degeneration treatments trials (CATT)JAMA Ophthalmol2014132552152724652518
   PubMed Web of Science ®Google Scholar
• HagstromSAYingGSPauerGJComparison of AMD Treatments Trials Research GroupPharmacogenetics for genes associated with age-related macular degeneration in the Comparison of AMD Treatments Trials (CATT)Ophthalmology2013120359359923337555
   PubMed Web of Science ®Google Scholar
• HermannMMvan AstenFMuetherPSPolymorphisms in vascular endothelial growth factor receptor 2 are associated with better response rates to ranibizumab treatment in age-related macular degenerationOphthalmology2014121490591024365177
   PubMed Web of Science ®Google Scholar
• ChenYZengJZhaoCAssessing susceptibility to age-related macular degeneration with genetic markers and environmental factorsArch Ophthalmol2011129334435121402993
   PubMed Web of Science ®Google Scholar
• GrassmannFFritscheLGKeilhauerCNHeidIMWeberBHModelling the genetic risk in age-related macular degenerationPloS One201275e3797922666427
   PubMed Web of Science ®Google Scholar
• HagemanGSGehrsKLejnineSClinical validation of a genetic model to estimate the risk of developing choroidal neovascular age-related macular degenerationHum Genomics20115542044021807600
   PubMedGoogle Scholar
• PerleeLTBansalATGehrsKInclusion of genotype with fundus phenotype improves accuracy of predicting choroidal neovascularization and geographic atrophyOphthalmology201312091880189223523162
   PubMed Web of Science ®Google Scholar
• SobrinLSeddonJMNature and nurture-genes and environment-predict onset and progression of macular degenerationProg Retin Eye Res20144011524374240
   PubMed Web of Science ®Google Scholar
• KalfRRMihaescuRKunduSde KnijffPGreenRCJanssensACVariations in predicted risks in personal genome testing for common complex diseasesGenet Med2014161859123807614
   PubMed Web of Science ®Google Scholar
• BuitendijkGHAminNHofmanAvan DuijnCMVingerlingJRKlaverCCDirect-to-consumer personal genome testing for age-related macular degenerationInvest Ophthalmol Vis Sci201455106167617425146986
   PubMed Web of Science ®Google Scholar
• BuitendijkGHRochtchinaEMyersCPrediction of age-related macular degeneration in the general population: the Three Continent AMD ConsortiumOphthalmology2013120122644265524120328
   PubMed Web of Science ®Google Scholar
• DevMKPaudelNJoshiNDShahDNSubbaSImpact of visual impairment on vision-specific quality of life among older adults living in nursing homeCurr Eye Res201439323223824144491
   PubMed Web of Science ®Google Scholar
• RovnerBWCastenRJHegelMTLow vision depression prevention trial in age-related macular degeneration: a randomized clinical trialOphthalmology2014121112204221125016366
   PubMed Web of Science ®Google Scholar
• RovnerBWCastenRJHegelMTImproving function in age-related macular degeneration: a randomized clinical trialOphthalmology201312081649165523642378
   PubMed Web of Science ®Google Scholar
• ChristoforidisJBTecceNDell’OmoRMastropasquaRVerolinoMCostagliolaCAge related macular degeneration and visual disabilityCurr Drug Targets201112222123320887239
   PubMed Web of Science ®Google Scholar
• AlexanderMSLajoieKNeimaDRStrathRARobinovitchSNMarigoldDSEffect of ambient light and age-related macular degeneration on precision walkingOptom Vis Sci201491899099924987813
   PubMed Web of Science ®Google Scholar
• AlexanderMSLajoieKNeimaDRStrathRARobinovitchSNMarigoldDSEffects of age-related macular degeneration and ambient light on curb negotiationOptom Vis Sci201491897598924879086
   PubMed Web of Science ®Google Scholar
• WatsonGRLow vision in the geriatric population: rehabilitation and managementJ Am Geriatr Soc200149331733011300245
   PubMed Web of Science ®Google Scholar
• StelmackJATangXCRedaDJRinneSMancilRMMassofRWLOVIT Study GroupOutcomes of the Veterans Affairs Low Vision Intervention Trial (LOVIT)Arch Ophthalmol2008126560861718474769
   PubMedGoogle Scholar
• GaffneyAJMargrainTHBunceCVBinnsAMHow effective is eccentric viewing training? A systematic literature reviewOphthalmic Physiol Opt201434442743724735182
   PubMed Web of Science ®Google Scholar
• HooperPJutaiJWStrongGRussell-MindaEAge-related macular degeneration and low-vision rehabilitation: a systematic reviewCan J Ophthalmol200843218018718347620
   PubMed Web of Science ®Google Scholar
• AmoreFMPaliottaSSilvestriVPiscopoPTurcoSReibaldiABiofeedback stimulation in patients with age-related macular degeneration: comparison between 2 different methodsCan J Ophthalmol201348543143724093192
   PubMed Web of Science ®Google Scholar
• PijnackerJVerstratenPvan DammeWVandermeulenJSteenbergenBRehabilitation of reading in older individuals with macular degeneration: a review of effective training programsNeuropsychol Dev Cogn B Aging Neuropsychol Cogn201118670873221992418
   PubMed Web of Science ®Google Scholar
• KeanePAde SalvoGSimDAGoverdhanSAgrawalRTufailAStrategies for improving early detection and diagnosis of neovascular age-related macular degenerationClin Ophthalmol2015935336625733802
   PubMed Web of Science ®Google Scholar
• LaiKLandaGCurrent choice of treatments for neovascular AMDExpert Rev Clin Pharmacol20158113514025487081
   PubMed Web of Science ®Google Scholar
• SingerMAdvances in the management of macular degenerationF1000Prime Rep201462924860651
   PubMedGoogle Scholar